Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.

Verified May 2005 by National Cancer Institute (NCI).
Recruitment status was Active, not recruiting

Sponsor:

Information provided by:

National Cancer Institute (NCI)

ClinicalTrials.gov Identifier:

NCT00066274

First received: August 6, 2003

Last updated: January 10, 2009

Last verified: May 2005

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Becouarn Y, Senesse P, Thezenas S, Boucher E, Adenis A, Cany L, Jacob J, Cvitkovic F, Montoto-Grillot C, Ychou M. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Federation Nationale des Centres de Lutte Contre le Cancer. Ann Oncol. 2007 Sep 4; [Epub ahead of print]

Becouarn Y, Ychou M, Boucher E, et al.: A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (CPT-11 + oxaliplatin [IRINOX]) and two standard arms (LV5-FU2 + CPT-11 [FOLFIRI], LV5-FU2 + oxaliplatin [FOLFOX] in first line metastatic colorectal cancer (MCRC) (FNCLCC Accord 08). [Abstract] J Clin Oncol 24 (Suppl 18): A-3586, 2006.

To Top